Restore Medical Announces Date of Special Meeting
02 Giugno 2008 - 9:05PM
Business Wire
Restore Medical, Inc. (NASDAQ:REST) today announced that it has
scheduled a special stockholders� meeting to approve its proposed
merger transaction with Medtronic, Inc. (NYSE:MDT) for Wednesday,
July 16, 2008, at 10:30 a.m. CDT at the offices of Dorsey &
Whitney LLP located at 50 South Sixth Street, Minneapolis,
Minnesota 55402. Stockholders of record as of the close of business
on June 6, 2008, will be entitled to vote at the meeting. Bob
Paulson, president and chief executive officer of Restore Medical,
said, �The board of directors believes that the merger transaction
with Medtronic is in the best interests of the company and our
stockholders. Because a non-vote will have the same effect as a
vote against approving the transaction, we urge our stockholders to
exercise their rights by voting their shares as soon as possible
after they receive and review the proxy statement.� ADDITIONAL
INFORMATION ABOUT THIS TRANSACTION Restore Medical plans to file
with the Securities Exchange Commission (�SEC�) and mail to its
stockholders a definitive proxy statement in connection with the
transaction on or around June 11, 2008. The proxy statement will
contain important information about Restore Medical, the proposed
merger and related matters. Stockholders are urged to read the
proxy statement regarding the proposed merger when it becomes
available because it will contain important information that
stockholders should consider before making a decision about the
merger. A free copy of the proxy statement (when available) and
other related documents filed by Restore Medical with the SEC can
be obtained by accessing the SEC�s website at www.sec.gov. The
proxy statement (when available) and the other documents also may
be obtained at no charge by (i) accessing Restore Medical�s website
at www.restoremedical.com, clicking on the �About Restore Medical�
link, followed by the �Investor Relations� link, and then the �SEC
Filings� heading; (ii) writing to Restore Medical at 2800 Patton
Road, St. Paul, MN 55113, Attention: Christopher Geyen, CFO; or,
(iii) emailing Christopher Geyen at cgeyen@restoremedical.com.
Restore Medical and its directors, executive officers and certain
other members of management and employees, along with certain of
its authorized representatives, may be soliciting proxies from
Restore Medical�s stockholders in favor of the merger. Information
regarding the individuals who may, under the rules of the SEC, be
considered participants in the solicitation of Restore Medical�s
stockholders in connection with the proposed merger will be set
forth in the proxy statement when it is filed with the SEC.
Information about Restore Medical�s executive officers and
directors can be found in the Company�s annual report on Form
10-K/A for the year ended December 31, 2007 filed with the SEC on
April 25, 2008. Free copies of these documents can be obtained from
Restore Medical using the contact information listed above.
FORWARD-LOOKING STATEMENTS This press release contains
forward-looking statements, which involve a number of risks and
uncertainties. Restore Medical cautions readers that any
forward-looking information is not a guarantee of future
performance and that actual results could differ materially from
those contained in the forward-looking information. Forward looking
statements include, but are not limited to, statements about the
benefits of the business combination transaction involving
Medtronic and Restore Medical, including future financial and
operating results, post-acquisition plans, objectives, expectations
and intentions and other statements that are not historical facts.
The following factors, among others, could cause actual results to
differ from those set forth in the forward-looking statements: the
failure of Restore Medical�s stockholders to approve the
transaction; the risk that the businesses will not be integrated
successfully; the risk that the cost savings and any other
synergies from the transaction may not be fully realized or may
take longer to realize than expected; disruption from the
transaction making it more difficult to maintain relationships with
customers, employees or suppliers; and competition and its effect
on pricing, spending, third-party relationships and revenues.
Additional factors that may affect future results are contained in
Restore Medical�s filings with the SEC, which are available at the
SEC�s web site http://www.sec.gov. Restore Medical disclaims any
obligation to update and revise statements contained in these
materials based on new information or otherwise. ABOUT RESTORE
MEDICAL Restore Medical develops, manufactures and markets
innovative medical devices to treat sleep-disordered breathing. The
Company�s proprietary Pillar� Palatal Implant System is the only
implantable palatal device to treat snoring and mild to moderate
obstructive sleep apnea to be cleared by the U.S. Food and Drug
Administration and by Health Canada, and to have received the CE
Mark for sale in the European Union. The Pillar Palatal Implant
System is sold throughout the U.S. and Canada, and in various
countries in Asia Pacific, Europe, South America and the Middle
East. For more information about Restore Medical, the Pillar
Procedure and physicians who offer the Pillar Procedure in the
U.S., visit the Company�s website at www.restoremedical.com or
www.pillarprocedure.com.
Grafico Azioni Restore Medical (MM) (NASDAQ:REST)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Restore Medical (MM) (NASDAQ:REST)
Storico
Da Set 2023 a Set 2024